logo-loader

Motif BIo chief “very confident” for Phase III iclaprim trial

Published: 15:02 02 Mar 2016 GMT

Graham Lumsden, chief executive of Motif Bio (LON:MTFB), says he is “very confident” in the firm’s Phase III study for its next-generation antibiotic, iclaprim.

The firm passed a major milestone when it dosed its first patient in one of two phase III clinical trials on Wednesday.

Lumsden says it is a “huge accomplishment by the team at Motif,” and “great news for shareholders”.

The studies, which will assess the drug’s potential in treating acute bacterial skin and skin structure infection, will look at efficacy and safety and compare them with the standard treatment vancomycin.

Ariana Resources updates resource and reserve; realises long-term strategy

Joining Jonathan Jackson in the Proactive studio is Ariana Resources PLC (AIM:AAU) managing director Kerim Sener, who sits down to discuss the latest resource and reserve update for the Zenit Mining Operations in Western Türkiye. The update encompasses the Kiziltepe and Tavsan sectors, operated...

5 hours, 18 minutes ago